Hunan Warrant Pharmaceutical Co.Ltd(688799)
Work report of the board of directors in 2021
In 2021, the board of directors of Hunan Warrant Pharmaceutical Co.Ltd(688799) (hereinafter referred to as ” Hunan Warrant Pharmaceutical Co.Ltd(688799) ” or “the company”) performed its duties and exercised its powers in strict accordance with the relevant provisions of the company law, the securities law, the rules for listing shares on the science and innovation board of Shanghai Stock Exchange, the articles of association and the rules of procedure of the board of directors, and in the attitude of being responsible to all shareholders, Earnestly implement the resolutions of the general meeting of shareholders, effectively carry out the work of the board of directors, and ensure the good operation and sustainable development of the company. The work of the board of directors in 2021 is reported as follows:
1、 Overall operation of the company in 2021
2021 is the first year of the 14th five year plan, and the operation of the national economy shows a trend of stable recovery and sustainable development Hunan Warrant Pharmaceutical Co.Ltd(688799) adhering to the enterprise tenet of “science and technology serve health”, following the enterprise business philosophy of “concentrate on pharmacy and treat people with integrity”, adhering to the professional development path, taking innovation as the guide, quality as the guarantee and service as the support, we will orderly promote the coordinated development of R & D, production and sales of the company.
In 2021, the company realized an operating revenue of 1146599 million yuan, an increase of 20.61% year-on-year; The net profit attributable to the owners of the parent company was 1607607 million yuan, a year-on-year increase of 10.85%. By the end of the reporting period, the total assets of the company were 1797534 million yuan, an increase of 95.15% over the end of the previous year; The owner’s equity attributable to the parent company was 14794653 million yuan, an increase of 123.13% over the end of last year.
On July 13, 2021, the company was listed on the science and Innovation Board of Shanghai Stock Exchange and successfully landed in the capital market. The successful listing not only provides sufficient financial guarantee for the company’s product R & D and market development, but also further improves the company’s brand value, lays a solid foundation for the company’s talent introduction, industrial chain improvement, market development, industrial restructuring and M & A to achieve leapfrog development, and the company’s development has entered a new stage.
2、 Main work of the board of directors in 2021
In 2021, the company’s governance work was carried out in an orderly manner. All directors of the company faithfully and diligently performed their duties, the operation of the general meeting of shareholders and the board of directors was standardized, and all resolutions were effectively implemented. Independent directors actively offered suggestions and played a positive role in improving the company’s supervision mechanism and safeguarding the legitimate rights and interests of the company and all shareholders. The special committees of the board of directors operate according to law, which effectively improves the scientificity of the company’s decision-making.
On October 27, 2021, the company held the first meeting of the third board of directors, completed the general election of the chairman, vice chairman and special committees of the board of directors, and completed the appointment of the new senior management, securities affairs representative, head of internal audit and chief scientist.
(I) convening of the board meeting
During the reporting period, the board of directors of the company held 7 meetings and considered and adopted 46 proposals related to periodic reports and related party transactions. The convening and convening procedures, the qualifications of participants and voting procedures of the meeting were in line with relevant laws and regulations and the relevant provisions of the company’s charter, and the resolutions of the meeting were legal and effective. The details are as follows:
Date of meeting name of meeting voting on proposals
1. Proposal on confirmation of related party transactions of the company in 2020; The second session of the board of directors in February 2021 2. Proposal on reviewing, confirming and agreeing to take the company’s 2020 audit report as the application material for public offering of shares and listing on the science and Innovation Board at the seventh meeting on February 28 of the first time;
3. Proposal on proposing to convene the first extraordinary general meeting of shareholders in 2021.
1. Proposal on the company’s 2020 annual report and the summary of 2020 annual report;
2. Proposal on the company’s 2020 financial final accounts report;
3. Proposal on the company’s profit distribution plan in 2020;
4. Proposal on the company’s 2021 annual financial budget report;
5. Proposal on the prediction of related party transactions of the company in 2021;
6. Proposal on the work report of the board of directors in 2020;
The second session of the board of directors in March 2021 7. Proposal on the work report of the general manager of the company in 2020;
August 29 8th meeting 8. Proposal on the appointment of senior managers of the company;
9. Proposal on the company’s renewal of annual audit institution;
10. Proposal on Hunan Warrant Pharmaceutical Co.Ltd(688799) establishing a special asset management plan for senior executives and core employees to participate in the strategic placement scheme of initial public offering of shares on the science and innovation board;
11. Proposal on convening the 2020 annual general meeting of shareholders of the company;
12. Proposal on formulating the remuneration management system for directors, supervisors and senior managers of the company.
1. Proposal on changing the registered capital and company type of the company, amending the articles of association and handling the industrial and commercial change registration;
2. Proposal on adjusting the amount of raised funds to be invested in investment projects with raised funds; 3. Proposal on increasing the implementation subject of some investment projects with raised funds;
The second session of the board of directors in August 2021 4. Proposal on using part of the raised funds to provide interest free loans to wholly-owned subsidiaries to implement the project investment at the 9th meeting on April 4;
5. Proposal on using part of the temporarily idle raised funds for cash management; 6. Proposal on using self owned funds to purchase financial products;
7. Proposal on using self owned funds and bank acceptance bills to pay the funds required for raised investment projects and replacing them with raised funds in equal amount.
The second session of the board of directors in August 2021 1 1. Proposal on the company’s 2021 semi annual report and its summary;
At the 10th meeting on June 26, 2. Proposal on using raised funds to replace self raised funds invested in raised investment projects in advance and paid issuance expenses.
1. Proposal on the general election of the board of directors of the company and the nomination of non independent directors of the third board of directors;
The second session of the board of directors in October 2021 2. The proposal of the 11th meeting on the election of the board of directors and the nomination of independent directors of the third session of the board of directors on October 9;
3. Proposal on amendment of the articles of Association;
4. Proposal on convening the second extraordinary general meeting of shareholders in 2021.
1. Proposal on electing the chairman of the third board of directors of the company;
2. Proposal on electing the vice chairman of the third board of directors of the company;
3. Proposal on the election of members of the special committee of the third board of directors of the company;
4. Proposal on appointing the general manager of the company;
The third session of the board of directors in October 2021 5. Proposal on the appointment of the company’s deputy general manager;
The first meeting on June 27 6. Proposal on the appointment of the company’s financial director;
7. Proposal on appointing the Secretary of the board of directors of the company;
8. Proposal on appointment of securities affairs representative of the company;
9. Proposal on appointing the person in charge of internal audit of the company;
10. Proposal on appointing chief scientist of the company
11. Proposal on the third quarter report of the company in 2021.
1. Proposal on renewing the appointment of accounting firms;
2. Proposal on Revising the remuneration management system of directors, supervisors and senior managers of the company;
The third session of the board of directors in December 2021 3. Proposal on Amending the management system of related party transactions of the company;
The second meeting on June 14 4. Proposal on Revising the company’s investor relations management system;
5. Proposal on Amending the registration and management system of insiders of the company;
6. Proposal on increasing the forecast of daily connected transactions in 2021;
7. Proposal on convening the third extraordinary general meeting of shareholders in 2021.
(II) implementation of resolutions of the general meeting of shareholders by the board of directors
In 2021, four general meetings of shareholders were held and 19 proposals were considered and adopted. The convening, proposal, attendance, discussion, voting and resolution of the general meeting of shareholders are operated in strict accordance with the requirements of relevant laws and regulations, the articles of association and the rules of procedure of the general meeting of shareholders. The board of directors carefully implemented and completed all resolutions adopted by the general meeting of shareholders in strict accordance with the resolutions and authorization of the general meeting of shareholders. The details are as follows:
Date of meeting name of meeting voting on proposals
The first time in March 2021 1 1. Proposal on confirming the related party transactions of the company in 2020; On June 16, the extraordinary general meeting of shareholders 2. Proposal on examining, confirming and agreeing to take the company’s 2020 audit report as the application material for initial public offering and listing on the science and innovation board.
1. Proposal on the company’s 2020 annual report and the summary of 2020 annual report; 2. Proposal on the company’s 2020 financial final accounts report;
2021 April 2020 annual shares 3. Proposal on the company’s profit distribution plan in 2020;
April 20 East Conference 4. Proposal on the company’s 2021 annual financial budget report;
5. Proposal on the prediction of related party transactions of the company in 2021;
6. Proposal on the work report of the board of directors in 2020;
7. Proposal on the work report of independent directors of the company in 2020;
8. Proposal on the work report of the board of supervisors in 2020;
9. Proposal on the company’s renewal of annual audit institution;
10. Proposal on formulating the remuneration management system for directors, supervisors and senior managers of the company.
